Patients suffering with finger pain caused by Raynaud’s Syndrome are needed to participate in a clinical trial at Southern Illinois University School of Medicine’s Division of Plastic Surgery. The randomized, double-blind clinical trial examines the effect of using Botox® to relieve pain by increasing blood flow. SIU is the only site in the United States
This recently published press release from the UC Davis School of Medicine may provide insights into the cause and treatment for Raynaud’s:
Survey is now closed. We had an awesome response - thanks for your support! Orion Pharma, a pharmaceutical company based in Finland, would like to gather information about Raynaud’s from people suffering from this condition. The data gathered in the research will be used by Orion to help develop a new class of medication for Raynaud's patients.
Modified-Release Therapy is Well Tolerated in Clinical Trial Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud’s phenomenon in patients with limited cutaneous systemic sclerosis (lcSSc), also known as scleroderma. The double-blind, placebo-controlled trial found that sildenafil was well tolerated with only some subjects experiencing minor
Raynaud’s patients are being recruited for clinical trials of a new drug. Doctors seek study participants who: Are male or female between 18 and 65 years of age Have active Raynaud’s Phenomenon triggered by cold or stress Have at least 7 Raynaud’s attacks per week on 5 or more days per week